Sarepta CEO receives 2,224,342 options and 756,104 RSUs

Sarepta Therapeutics, Inc. reported that Chief Executive Officer Michael Severino received significant equity awards on 2026-07-28.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. reported that Chief Executive Officer Michael Severino received significant equity awards on 2026-07-28. He was granted 2,224,342 stock options with a $17.74 exercise price, expiring 2036-07-28; 25% vests on 2027-07-28 and the remainder vests monthly over four years. He also received 756,104 restricted stock units, each for one share of common stock, vesting in substantially equal annual installments over four years, bringing his reported direct holdings to 2,224,342 options and 756,104 shares.

Insider Trade Summary

Grant/Award: 2,980,446 shares

Grant/Award 2 txns

Insider SEVERINO MICHAEL

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy) F2	2,224,342	$0.00	$0.00
Grant/Award	Common Stock F1	756,104	--	--

Holdings After Transaction: Stock Options (right to buy) — 2,224,342 contracts (Direct); Common Stock — 756,104 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.
2. F2. Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.

Key Figures

Stock options granted: 2,224,342 shares Exercise price: $17.74 per share RSUs granted: 756,104 units +4 more

7 metrics

Stock options granted 2,224,342 shares Stock options granted to CEO Michael Severino on 2026-07-28

Exercise price $17.74 per share Exercise price of options granted on 2026-07-28

RSUs granted 756,104 units Restricted stock units granted to Michael Severino on 2026-07-28

Option expiration date 2036-07-28 Expiration date for the granted stock options

Initial option vesting date 2027-07-28 Date when first 25% of options vest

Post-grant common stock holdings 756,104 shares Total direct common stock holdings after RSU grant

Post-grant option holdings 2,224,342 options Total direct option holdings after grant

Key Terms

restricted stock units ("RSUs"), Stock Options (right to buy), vests and becomes exercisable, monthly anniversary

4 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Options (right to buy) financial

"Security title listed as Stock Options (right to buy)."

vests and becomes exercisable financial

"1/48th of the total granted option vests and becomes exercisable on each monthly anniversary."

monthly anniversary financial

"1/48th of the total granted option vests on each monthly anniversary thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for its CEO?

Sarepta reported that CEO Michael Severino received stock option and RSU grants on 2026-07-28. The awards include options over 2,224,342 shares and 756,104 RSUs, both subject to multi-year vesting tied to continued employment.

How many stock options were granted to Sarepta (SRPT) CEO Michael Severino and on what terms?

Michael Severino was granted 2,224,342 stock options with an exercise price of $17.74 per share. The options expire on 2036-07-28, with 25% vesting on 2027-07-28 and the remaining 75% vesting in equal monthly installments over four years.

What are the vesting conditions for the Sarepta (SRPT) CEO’s new stock options?

The options begin vesting when 25% of the grant vests on 2027-07-28. After that, 1/48th of the total granted options vests and becomes exercisable on each monthly anniversary, contingent on Michael Severino’s continued employment with Sarepta.

What RSU grant did Sarepta (SRPT) award to its CEO and how does it vest?

Sarepta granted Michael Severino 756,104 restricted stock units (RSUs), each representing one common share. These RSUs vest in substantially equal installments on an annual basis over four years from the grant date, subject to his continued employment with the company.

What are Michael Severino’s reported Sarepta (SRPT) holdings after these equity awards?

After the reported grants, Michael Severino’s direct holdings are 2,224,342 stock options and 756,104 shares of common stock. These figures reflect totals reported following the 2026-07-28 transactions for the respective derivative and non-derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 08:05 PM Accepted by SEC EDGAR 07/29/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEVERINO MICHAEL

(Last) (First) (Middle)

215 FIRST STREET

(Street)

MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		756,104	A	(1)	756,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$17.74	07/28/2026		A		2,224,342		07/28/2027(2)	07/28/2036	Common Stock	2,224,342	$0	2,224,342	D

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in substantially equal installments on an annual basis over four years from the date of grant, subject to the Reporting Person's continued employment.

2. Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continued employment.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Severino	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)